Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (407)	2/12/1999 9:57:00 PM
From: Merritt	Respond to of 613

Rick: I'm no expert, but I did some lab work for an M.E. who was also a pathologist when I was in the service...about 40 years ago.<G> He was of the opinion that just about everyone over the age of 21 had some malignancies, but for some reason, they were held in check. I've felt that the increased incidence of cancer in children who were within 100 feet of electric transmission line transformers was because of likely electro/magnetic interference in the body's signaling mechanisms. I don't think the electrical interference causes cancer, but rather that it allows it, in some instances, to grow. There's also a higher incidence of cancer in electrical linemen, welders, and electricians. I really don't believe that's just coincidence. I also don't believe the government wants to know...it's a case of acceptable losses for the common good. Well, that's my unscientific 'crackpot' contribution.<G>

To: scaram(o)uche who wrote (407)	2/13/1999 6:41:00 AM
From: Arthur Radley	Respond to of 613

TV: CNNfn; Your Money, 2/12 11:30 PM <summary> Biotech is back, after a depressing decade biotechnology stocks are poised to take the spotlight again. Watch for companies with "at least three years cash on hand, plans to market their own products and a full pipeline Would it not be nice if the above is the case?

To: scaram(o)uche who wrote (407)	2/13/1999 2:52:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 613

Rick, your EXPERT opinion is needed. I have a position in ATRX, and their major technology is a drug delivery system called ATRIGEL. It is a biodegradable polymeric system that works by the body's own moist environment turning the delivered drug into a site specific timed released implant. They currently have FDA approval for ATRIDOX for treatment in the periodontal disease area in which the ATRIGEL system is the delivery system. My question to you relates to their planned human trials with their ATRIGEL system in the treatment of prostate cancer. They plan to deliver leuprolide acetate as a site specific drug in a 30 day delivery time-frame. How effective is leuprolide acetate? What I've been able to determine is that it is a $1.5 billion dollar drug and I wonder if such a delivery system by ATRX would enhance its performance as a cancer fighter. As always, thanks for your input. Cary